Scholarlink

<p>Glioma is an aggressive malignancy characterized by an immunosuppressive tumor microenvironment (TME) that drives therapeutic resistance. <i>MET</i> alterations promote tumor progression and immune evasion, yet their clinical implications in glioma immunotherapy remain unclear. Here, we integrated multi-omics data from four independent cohorts to establish a MET-associated immune prognostic signature (MIPS) comprising 18 immune-related genes. MIPS effectively stratified glioma patients into low- and high-MIPS subgroups. High-MIPS patients exhibited significantly poorer overall survival than low-MIPS patients across all cohorts and was an independent prognostic factor independent of clinicopathological and molecular features. High-MIPS scores correlated with increased M2 macrophage infiltration, elevated B7-H3 expression, and higher TIDE scores, indicating immunotherapy resistance. Bioinformatic prediction and patient-derived organoid assays verified that low-MIPS tumors were sensitive to multiple targeted drugs (e.g., Axitinib, AZD-8055, Gefitinib, and Lenalidomide), while high-MIPS tumors were relatively resistant. MIPS derived from <i>MET</i> alteration serves as a robust biomarker for prognosis and predictive tool for immunotherapy and chemotherapy, facilitating patient stratification and precision therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MET-associated immune prognostic signature predicts survival and guides personalized therapy in glioma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Ying Zhang,
  • Chengjun Zheng,
  • Qiaodong Chen,
  • Wenlu Tan,
  • Fei Liu,
  • Zheng Fang,
  • Hanxiao Zhou,
  • Changyuan Ren,
  • Jinhao Zhang,
  • Changlin Yang,
  • Menghui Xu,
  • Lingxiang Wu,
  • Ji Shi,
  • Zheng Zhao,
  • Zhaoshi Bao

摘要

Glioma is an aggressive malignancy characterized by an immunosuppressive tumor microenvironment (TME) that drives therapeutic resistance. MET alterations promote tumor progression and immune evasion, yet their clinical implications in glioma immunotherapy remain unclear. Here, we integrated multi-omics data from four independent cohorts to establish a MET-associated immune prognostic signature (MIPS) comprising 18 immune-related genes. MIPS effectively stratified glioma patients into low- and high-MIPS subgroups. High-MIPS patients exhibited significantly poorer overall survival than low-MIPS patients across all cohorts and was an independent prognostic factor independent of clinicopathological and molecular features. High-MIPS scores correlated with increased M2 macrophage infiltration, elevated B7-H3 expression, and higher TIDE scores, indicating immunotherapy resistance. Bioinformatic prediction and patient-derived organoid assays verified that low-MIPS tumors were sensitive to multiple targeted drugs (e.g., Axitinib, AZD-8055, Gefitinib, and Lenalidomide), while high-MIPS tumors were relatively resistant. MIPS derived from MET alteration serves as a robust biomarker for prognosis and predictive tool for immunotherapy and chemotherapy, facilitating patient stratification and precision therapy.